SCHEMBL9892659

SCHEMBL9892659

O=C(O)Cc1cc(C(F)(F)F)ccc1-c1ccc(Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 6/20 0.59
PSEN1 P49768 1/20 0.56
PSEN2 P49810 1/20 0.56
APH1B Q8WW43 1/20 0.56
NCSTN Q92542 1/20 0.56
APH1A Q96BI3 1/20 0.56
PSENEN Q9NZ42 1/20 0.56
RXRA P19793 4/20 0.48
RXRB P28702 4/20 0.48
RXRG P48443 4/20 0.48
DHODH Q02127 1/20 0.46
ANO1 Q5XXA6 1/20 0.46
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
TBXA2R P21731 1/20 0.45
PTGIR P43119 1/20 0.45
PTGDR Q13258 1/20 0.45
KDM1A O60341 1/20 0.45
THRB P10828 1/20 0.45
GCGR P47871 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890676 0.91 PSEN1 (0.59) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL9892683 0.87 PTGDR2 (0.51) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL9892653 0.87 PSEN1 (0.56) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL9892693 0.84 PTGDR2 (0.48) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL3745897 0.83 KEAP1 (0.47) PTGDR2CYP2C9GCGRMAPT
SCHEMBL9890672 0.81 PSEN1 (0.61) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL3736882 0.81 AKR1C3 (0.49) PTGDR2DHODHANO1
SCHEMBL3738753 0.80 RXRA (0.48) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL2397285 0.79 PSEN1 (0.48) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL1775542 0.79 ALDH1A1 (0.52) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGDR2 1062/4885PSEN1 2126/4885PSEN2 1867/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGDR2 1062/4885PSEN1 2126/4885PSEN2 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.